FAGR Fagron SA

Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting

Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 12 April 2024 – 8AM CET

Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting

The Board of Directors of Fagron NV invites shareholders to attend Fagron’s annual general meeting of shareholders and the extraordinary general meeting of shareholders on Monday 13 May 2024.

Agenda

The agenda includes the discussion of the annual report, the approval of the annual financial statements and the dividend proposal of €0.30 for the financial year 2023, and the approval of the remuneration policy. The remuneration policy provides for an increase in the annual remuneration of the non-executive directors. Furthermore, the agenda includes the proposal to reappoint Robert ten Hoedt as independent, non-executive director. The full agenda and further details can be found in the meeting documents.

Meeting and meeting documents

Fagron’s annual general meeting of shareholders will be held at its statutory seat, Venecoweg 20A, 9810, Nazareth (Belgium) and by audio and video conference on Monday 13 May 2024 at 3PM CET. Immediately thereafter, the extraordinary general meeting will be held in the presence of associated civil-law notary Stijn Raes.

The convocation, including the agenda, and other documents related to both general meetings of shareholders can be found on the Fagron .

Further information

Karen Berg

Global Investor Relations Manager

Tel. 99

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 30 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment



EN
12/04/2024

Underlying

FAGRFagron SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

Frank Claassen
  • Frank Claassen
FAGR FAGRON SA

Fagron - Compounding for growth

•    New 40p report: Fagron is an excellent play on the structural growth drivers of personalized medication (e.g. demographics, drug shortages). •    It has high visibility on high single digit organic growth and in combination with Buy-and-build this offers double digit EBITDA growth.•    We reiterate our Buy with a TP of EUR 24 (was EUR 23) based on our SOTP and DCF on the back of 2% higher EBITDA estimates following Q1.

04/22/24 April 22, 2024 1 EN
Thomas Vranken
  • Thomas Vranken
FAGR FAGRON SA

Fagron Growth engine keeps running

We updated our model following Fagron's recent 1Q24 update. While our prior estimates for FY24 and beyond largely remain in place, we pay special attention to Fagron's North American compounding services (CS) business (Boston/Wichita + Anazao), as well as the impact of the recent Polish regulatory change. Overall, our valuation continues to point to a TP of € 22, hence we maintain a Buy rating.

04/15/24 April 15, 2024 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Fagron publishes agenda for 2024 annual shareholders meeting and extra...

Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 April 2024 – 8AM CET Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting The Board of Directors of Fagron NV invites shareholders to attend Fagron’s annual general meeting of shareholders and the extraordinary general meeting of shareholders on Monday 13 May 2024. AgendaThe agenda includes the discussion of the annual report, the approval of the annual financial stateme...

April 12, 2024 1 EN
Thomas Vranken
  • Thomas Vranken
FAGR FAGRON SA

Fagron FIRST LOOK: 1Q24 conference call feedback

Following our earlier note on the 1Q24 results (LINK), we share our main takeaways from the conference call hosted by Fagron to discuss its 1Q24 results.

04/11/24 April 11, 2024 1 EN
Oliver Metzger
  • Oliver Metzger
ROG Roche Holding L...
OSE OSE Immunothera... ... (+14)

ODDO BHF Small & MIDCAP MORNING NEWS - 04/11/2024

Waga Energy offers an innovative start-up profile in the utilities sector: i/ disruptive technology in biogas treatment, ii/ established competitive advantages, iii/ positioning on a market with strong potential (>20,000 landfills) and iv/ a robust business model based on recurring revenues. At its CMD in February 2024, the company reconfirmed its ambitions for 2026 set out at the IPO (contracts for 4 TWh and recurring revenues of € 200m). The financing secured in Q1 2024 (€ 112m base...

ROG ROCHE HOLDING LTD
OSE OSE IMMUNOTHERAPEUTICS SA
NOVN NOVARTIS AG
TFI TELEVISION FRANCAISE 1 SA
GXI GERRESHEIMER AG
FAGR FAGRON SA
BOSS HUGO BOSS AG
A1XA4J CARBIOS SA
SAN SANOFI
SLIGR SLIGRO FOOD GROUP N.V.
AZN ASTRAZENECA PLC
ALVGO VOGO SA
GSK GSK PLC
NOVO B NOVO NORDISK A/S
04/11/24 April 11, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch